Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
出版年份 2023 全文链接
标题
Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
作者
关键词
-
出版物
Cancers
Volume 15, Issue 5, Pages 1569
出版商
MDPI AG
发表日期
2023-03-03
DOI
10.3390/cancers15051569
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
- (2022) Ivana Samaržija et al. Cancers
- EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes
- (2022) Jinqiang Zhang et al. AMERICAN JOURNAL OF PATHOLOGY
- Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
- (2022) Haruka Shinohara et al. Molecular Therapy-Oncolytics
- Tazemetostat: First Approval
- (2020) Sheridan M. Hoy DRUGS
- EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma
- (2020) Jessamy Tiffen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Long Non-Coding RNAs in Biliary Tract Cancer—An Up-to-Date Review
- (2020) Dino Bekric et al. Journal of Clinical Medicine
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
- (2020) Franck Morschhauser et al. LANCET ONCOLOGY
- Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives
- (2020) Noemi Simeone et al. Future Oncology
- Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer
- (2020) Xiao Tan et al. Cell Death & Disease
- EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy
- (2019) Julian Puppe et al. CLINICAL CANCER RESEARCH
- Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
- (2019) Florian Moik et al. Scientific Reports
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation
- (2019) Evan Healy et al. MOLECULAR CELL
- Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma
- (2019) Ni Wang et al. Cell Death & Disease
- EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway
- (2019) Hanwen Zhang et al. ONCOGENE
- Miniaturization of the Clonogenic Assay Using Confluence Measurement
- (2018) Christian Mayr et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting EZH2 with tazemetostat
- (2018) Shinichi Makita et al. LANCET ONCOLOGY
- Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway
- (2018) Wei Zhao et al. LIFE SCIENCES
- Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity
- (2017) Laurel T. Bate-Eya et al. EUROPEAN JOURNAL OF CANCER
- EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
- (2017) Dorothy Brach et al. MOLECULAR CANCER THERAPEUTICS
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
- (2016) Jacson K. Shen et al. Scientific Reports
- The role of polycomb repressive complexes in biliary tract cancer
- (2014) Christian Mayr et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3
- (2014) Bo Tang et al. MEDICAL ONCOLOGY
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- EZH2 Regulates the Expression of p16 in the Nasopharyngeal Cancer Cells
- (2013) Jing Zhong et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Current status of chemotherapy for the treatment of advanced biliary tract cancer
- (2013) Takashi Sasaki et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma
- (2011) Dong-Cai Liu et al. PATHOLOGY RESEARCH AND PRACTICE
- Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
- (2010) Sha Hu et al. CANCER BIOLOGY & THERAPY
- Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
- (2010) Martin Sauvageau et al. Cell Stem Cell
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Management of Gallbladder Carcinoma
- (2010) A. X. Zhu et al. ONCOLOGIST
- Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma
- (2009) Junpei Yamaguchi et al. CANCER SCIENCE
- Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin
- (2009) Junpei Yamaguchi et al. LABORATORY INVESTIGATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started